¹¹C‐PE2I and ¹⁸F‐Dopa PET for assessing progression rate in Parkinson's: A longitudinal study

Abstract

Striatal C-PE2I appears to show greater sensitivity for detecting differences in motor severity than F-dopa. Furthermore, dopamine transporter decline is closely associated with motor progression over time, whereas no such relationship was found with aromatic l-amino acid decarboxylase. C-PE2I may be more effective for evaluating the efficacy of neuroprotective treatments in PD. © 2017 International Parkinson and Movement Disorder Society.

Designing stem-cell-based dopamine cell replacement trials for Parkinson’s disease

“…In particular, the dopamine transporter (DAT) ligand 11 C-PE2I seemed to have a greater predictive value and sensitivity for detecting differences in motor impairment than AADC imaging using 18 F-DOPA. Furthermore, DAT decline seemed to be closely associated with the decline in motor progression over time, whereas no such relationship was found with AADC, suggesting that 11 C-PE2I is a more objective biomarker than 18 F-Dopa for investigating the effects of novel interventions 24 .…”

Pallidal dopaminergic denervation and rest tremor in early Parkinson's disease: PPMI cohort analysis

“…123 I-FP-CIT SPECT was performed during screening visits using standardized imaging were first rigid registered to an in-house custom DAT template created from a series of thirty-three 11 C-PE2I positron emission tomography scans, [8] which is a radioligand with high specificity for DAT. [9,10] Registered 123 I-FP-CIT images were then spatially normalized to this DAT template using 12-parameter affine registration and non-linear warping procedure in SPM12 (Statistical Parametric Mapping, Wellcome Trust Centre for Neuroimaging, London, UK).…”

Small Structural Changes at the N‐position of the Tropane Core Control the Mechanism of Nortropane Derivatives Binding to Dopamine Transporter

“…These results revealed that [ 3 H]WIN 35,428 (Figure ) was a far more effective radioligand than cocaine due to the slower dissociation rate of the ligand–protein complex, and this has made [ 3 H]WIN 35,428 the most widely used radioligand for characterization of DAT in vitro. Another tropane derivative, PE2I (Figure ), which is used extensively as a PET imaging agent to localize DAT, has been found to be at least as potent as WIN 35,428, but it has an even slower off‐rate . All of the numerous other studies with DAT‐specific tropane derivatives have focused on the determination of ligand affinity using conventional binding assays.…”